CR Sanjiu(SZ:000999) Xin Lang Cai Jing·2025-09-09 11:32Core Viewpoint - China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has completed the repurchase and cancellation of part of its restricted stock under the 2021 incentive plan, marking a significant milestone in the implementation of the incentive program [1][5]. Summary by Sections Incentive Plan Progress - The incentive plan was approved by the Compensation and Assessment Committee on September 15, 2021, and underwent multiple meetings and approvals before implementation [2]. - The company granted 8.24 million shares at a price of 14.84 yuan per share to 267 incentive targets on May 25, 2022, and an additional 1.206 million shares at 23.48 yuan per share to 131 targets on August 29, 2022 [2]. Repurchase and Cancellation Details - The repurchase involved 585,985 shares from 8 individuals who retired and 4 individuals who did not meet performance standards, accounting for approximately 0.04% of the company's total share capital [3]. - Additionally, 4,747,942 shares were repurchased due to unmet conditions for the third release period of the incentive plan, representing about 0.28% of the total share capital [3]. Repurchase Pricing and Financials - The repurchase price varied based on the reason for departure or performance issues, with some shares repurchased at an adjusted price of 5.7817625 yuan per share, plus interest for retirees [4]. - The total funds used for the repurchase amounted to 34,551,411.32 yuan, sourced from the company's own funds [4]. Implementation Progress - On July 8, 2025, the company announced the completion of the repurchase and cancellation process, with no creditor claims received during the public notice period [5]. - The cancellation of the restricted stock was finalized on September 9, 2025, with subsequent legal and registration procedures to follow [5].